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There is increasing evidence that the presence of a systemic inflammatory response plays an important role in survival following
curative resection for colorectal cancer. The present study evaluated the relationship between C-reactive protein concentrations and
survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for
colorectal cancer. In all, 222 patients undergoing potentially curative resection for colorectal cancer were studied. Of these, 50
patients received adjuvant 5-FU-based chemotherapy. Circulating concentrations of C-reactive protein were measured prior to
surgery. The minimum follow-up was 15 months; the median follow-up of the survivors was 38 months. During this period 61
patients died, 32 patients of their cancer and 29 of intercurrent disease. In those patients who did not receive adjuvant chemotherapy,
age (Po0.001), Dukes stage (Po0.05) and an elevated C-reactive protein (Po0.01) were significantly associated with survival. In
those patients who did receive adjuvant chemotherapy, an elevated C-reactive protein concentration (Po0.01) was significantly
associated with survival. The presence of a systemic inflammatory response is an independent predictor of poor outcome in patients
receiving adjuvant 5-FU-based chemotherapy following potentially curative resection for colorectal cancer.
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Colorectal cancer remains the second commonest cause of cancer
death in Western Europe and North America. Overall survival is
poor; even in those patients who undergo potentially curative
resection, more than one-third die within 5 years (McArdle and
Hole, 2002). In view of these poor results there is increasing
interest in the use of adjuvant chemotherapy.
Conventionally, in patients with primary operable colorectal
cancer, the decision whether or not to offer adjuvant 5-fluorouracil
(5-FU)-based chemotherapy is primarily based on the patient’s
age, pathological stage and fitness to tolerate chemotherapy.
However, even in this selected cohort, the impact of chemotherapy
on outcome is unpredictable. Therefore, there is continuing
interest in prognostic factors that better reflect clinical outcome
(Cascinu et al, 2003; Benson et al, 2004).
It has been demonstrated that the presence of a systemic
inflammatory response, as evidenced by elevated circulating
concentrations of C-reactive protein, is associated with increased
recurrence and poor survival, independent of Dukes stage, in
patients undergoing potentially curative surgery for colorectal
cancer (McMillan et al, 1995, 2003; Nielsen et al, 2000). However,
in these studies, few patients had received adjuvant chemotherapy.
It is therefore of considerable interest to examine whether this
poor outcome might also be found in patients receiving adjuvant
chemotherapy. Indeed, an elevated C-reactive protein has recently
been shown to be associated with poorer survival in patients
receiving chemotherapy for advanced lung cancer (Forrest et al,
2004) and renal cancer patients (Bromwich et al, 2004).
Therefore, the aim of the present study was to evaluate the
relationship between the systemic inflammatory response and
survival in a prospective cohort of patients receiving adjuvant
5-FU chemotherapy following potentially curative resection for
colorectal cancer.
PATIENTS AND METHODS
Patients
Patients with histologically proven colorectal cancer who, on the
basis of laparotomy findings and preoperative abdominal com-
puted tomography, were considered to have undergone a
potentially curative resection between January 1999 and June
2004 at Glasgow Royal Infirmary were included in the study. The
tumours were staged using conventional Dukes classification
(Dukes and Bussey, 1958). Patients who had preoperative radio-
therapy were excluded from the study since radiotherapy has been
reported to evoke a systemic inflammatory response (Cengiz et al,
2001; Koc et al, 2003).
Patients were selected for 5-FU-based chemotherapy following
discussion in the multidisciplinary group and taking into account
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stumour pathology, comorbidity and also patients’ wishes. This was
predominantly administered using the Mayo regimen for six cycles
(O’Connell et al, 1997).
A blood sample was taken for routine laboratory measurement
of C-reactive protein measurement immediately prior to surgery.
The limit of detection of the assay was a C-reactive protein
concentration lower than 6mgl
 1. The coefficient of variation,
over the range of measurement, was o5%, as established by
routine quality-control procedures. At this time no patient showed
clinical evidence of infection or other inflammatory condition.
The study was approved by the Research Ethics Committee,
Royal Infirmary, Glasgow.
Statistics
Comparisons between groups of patients were carried out using
contingency table analysis (X
2) as appropriate. Grouping of the
variables age and C-reactive protein was carried out using
standard thresholds (O’Gorman et al, 2000; Scottish Cancer
Intelligence Unit, 2000). Survival analysis of the group variables
was performed using the Cox proportional hazard model. Deaths
up to 31st August 2005 were included in the analysis. Multivariate
survival analysis, including all covariates was performed using a
stepwise backward procedure to derive a final model of the
variables that had a significant independent relationship with
survival. To remove a variable from the model, the corresponding
P-value had to be 40.10. Analysis was performed using SPSS
software (SPSS Inc., Chicago, IL, USA).
RESULTS
Two hundred and twenty-two patients undergoing potentially
curative resection for colorectal cancer were studied (Table 1). The
majority of patients were aged 65 years or more, had colonic
tumours and had C-reactive protein concentration in the normal
range (p10mgl
 1) prior to surgery.
Of the 222 patients, 50 received adjuvant 5-FU-based chemo-
therapy (Table 1). Those patients who received chemotherapy were
younger (Po0.001), more likely to be male (Po0.10), were more
likely to have Dukes C disease (Po0.001) and did not have
hypoalbuminaemia (Pp0.01). The groups were similar in terms of
site and C-reactive protein concentration.
The minimum follow-up was 15 months; the median follow-up
of the survivors was 38 months. During this period 61 patients
died, 32 patients of their cancer and 29 of intercurrent disease. On
univariate survival analysis, in those patients who did not receive
adjuvant chemotherapy, age (Po0.001), Dukes stage (Po0.05) and
an elevated C-reactive protein (Po0.01) were significantly
associated with survival (Table 2). In those patients who did
receive adjuvant chemotherapy, an elevated C-reactive protein
concentration (Po0.01) was significantly associated with survival.
On multivariate survival analysis, in those patients who did not
receive adjuvant chemotherapy, age (Po0.05) and an elevated C-
reactive protein (Po0.05) were independently associated with
Table 1 Clinicopathological characteristics in patients undergoing
potentially curative surgery with and without adjuvant 5-FU chemotherapy
for colorectal cancer
No adjuvant 5-FU Adjuvant 5-FU P-value
172 (%) 50 (%)
Age group (years)
o65 40 (23) 26 (52)
65–74 58 (34) 18 (36)
X75 74 (43) 6 (12) o0.001
Sex
Male 88 (51) 33 (66)
Female 84 (49) 17 (34) 0.064
Site
Colon 100 (58) 28 (56)
Rectum 72 (42) 22 (44) 0.788
Dukes stage
A 23 (13) 0 (0)
B 96 (56) 9 (18)
C 53 (31) 41 (82) o0.001
C-reactive protein
p10mgl
 1 95 (55) 32 (64)
410mgl
 1 77 (45) 18 (36) 0.270
Albumin
X35gl
 1 132 (77) 45 (90)
o35gl
 1 20 (12) 0 (0) 0.01
Alive 126 (74) 35 (70)
Dead
Cancer specific 23 (13) 9 (18)
Intercurrent 23 (13) 6 (12) 0.709
Table 2 Clinicopathological characteristics in patients undergoing potentially curative surgery and adjuvant 5-FU chemotherapy for colorectal cancer
(n¼222) and survival
No adjuvant chemotherapy (n¼172) Adjuvant chemotherapy (n¼50)
HR (95% CI) P-value HR (95% CI) P-value
Univariate analysis
Age (o65/65–74/X75) years 2.33 (1.48–3.68) o0.001 0.73 (0.31–1.71) 0.464
Sex (male/female) 1.37 (0.77–2.46) 0.287 1.55 (0.55–4.36) 0.411
Site (colon/rectum) 1.23 (0.69–2.21) 0.477 1.19 (0.43–3.29) 0.735
Dukes stage (A/B/C) 1.75 (1.06–2.89) 0.029 3.36 (0.44–25.85) 0.245
C-reactive protein (p10, 410mgl
 1) 2.39 (1.32–4.34) 0.004 6.68 (2.05–21.72) 0.002
Albumin (X35/o35gl
 1) 1.42 (0.59–3.40) 0.433
Multivariate analysis
Age (o65/65–74/X75) years 1.87 (1.13–3.09) 0.015 1.21 (0.47–3.15) 0.693
Sex (male/female) 1.08 (0.55–2.09) 0.828 0.92 (0.26–3.22) 0.894
Site (colon/rectum) 1.57 (0.81–3.07) 0.185 1.15 (0.31–4.27) 0.834
Dukes stage (A/B/C) 1.39 (0.82–2.36) 0.219 2.56 (0.31–21.21) 0.384
C-reactive protein (p10, 410mgl
 1) 2.10 (1.04–4.25) 0.039 5.57 (1.32–23.51) 0.019
Albumin (X35/o35gl
 1) 1.18 (0.48–2.88) 0.721
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chemotherapy, an elevated C-reactive protein concentration
(Po0.05) was independently associated with survival.
DISCUSSION
In the present study, an elevated C-reactive protein concentration
was associated with poorer survival, independent of age and Dukes
stage, in patients receiving adjuvant chemotherapy following
potentially curative resection for colorectal cancer. These results
would suggest that the systemic inflammatory response, as
evidenced by an elevated C-reactive protein concentration, is an
important factor in determining outcome in patients receiving
adjuvant 5-FU-based chemotherapy.
The basis of the relationship between the systemic inflammatory
response and poor survival in patients undergoing potentially
curative resection for colorectal cancer is not clear. The presence of
an elevated C-reactive protein concentration may simply reflect a
nonspecific inflammatory response secondary to tumour necrosis or
local tissue damage. However, these elevated C-reactive protein
concentrations do not appear to resolve following potentially
curative surgery in the majority of patients (McMillan et al, 2003).
Also, an elevated C-reactive protein concentration 3–6 months
following curative resection also has independent prognostic value
(McMillan et al, 1995, 2003). Therefore, these data suggest that the
systemic inflammatory response participates in the progression of
metastatic disease in patients with colorectal cancer.
There are a number of possible mechanisms by which this could
occur. Firstly, that an elevated C-reactive protein identifies those
patients with an impaired T-lymphocytic response, since poor
infiltration of gastrointestinal tumours appears to be associated
with poor outcome (Jass et al, 1987; Nielsen et al, 1999) and an
elevated C-reactive protein concentration has recently been shown
to be inversely associated with T-lymphocyte subset infiltration
(Canna et al, 2005). An alternative explanation is that an elevated
C-reactive protein concentration may identify those patients with a
proangiogenic environment, since increased angiogenesis is
associated with poor outcome in patients with colorectal cancer
(Salmon et al, 2005) and circulating concentrations of vascular
endothelial growth factor are directly associated with C-reactive
protein (Xavier et al, 2006). Clearly, both these inflammatory
mechanisms may be related and promote unrestrained tumour
growth and the dissemination required for the greater malignant
potential associated with an elevated C-reactive protein concentra-
tion.
In the present study, an elevated C-reactive protein concentra-
tion also predicted poor outcome in those patients receiving
adjuvant 5-FU-based chemotherapy. However, it has long been
recognised that progressive weight loss is associated with poor
tolerance to chemotherapy. For example, Andreyev et al (1998) in
a study of over 1500 patients who were to receive chemotherapy
for gastrointestinal cancer showed that prior weight loss was an
independent prognostic factor, and patients with weight loss
received less chemotherapy and developed more dose-limiting
toxicity. They concluded that there was a need to conduct
nutritional intervention studies in these patients.
More recently, it has been shown that the presence of an
ongoing systemic inflammatory response, as evidenced by an
elevated C-reactive protein concentration, predicts the progressive
nutritional decline of the patient with advanced gastrointestinal
cancer (Lundholm et al, 1994; McMillan et al, 1999; O’Gorman
et al, 1999). Moreover, recent work has shown that the activity of
the enzyme cytochrome P450 3A, which is involved in the
biotransformation of more than half of all drugs currently
available, is compromised in patients with an elevated C-reactive
protein concentration (Rivory et al, 2002; Slaviero et al, 2003;
Baker et al, 2004). It may therefore be that there is a need to carry
out studies to moderate the systemic inflammatory response rather
than nutritional intervention in patients receiving chemotherapy.
Irrespective of the mechanisms involved, we believe that the
presence or absence of a systemic inflammatory response should
be evaluated as a possible influence on outcome in future trials of
adjuvant chemotherapy in patients with colorectal cancer and
should be used in the stratification of patients. This is however a
small study and further larger studies are required to confirm these
results.
In summary, the presence of a systemic inflammatory response
appears to be an independent predictor of poor outcome in
patients receiving adjuvant 5-FU-based chemotherapy following
potentially curative resection for colorectal cancer.
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